首页 › 头颈鳞状细胞癌 › 明尼苏达州 › Minneapolis
Minneapolis MN 头颈鳞状细胞癌临床试验
9项针对 头颈鳞状细胞癌的研究正在 Minneapolis及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
招募中3 期
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 距离 5 英里
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
招募中2 期
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 距离 5 英里
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
招募中1/2 期
- Minnesota Oncology and Hematology PA, Minneapolis
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
招募中2 期
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Health Partners Inc, Minneapolis
- 以及另外 1 项
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
招募中1 期
- University of Minnesota Masonic Cancer Center, Minneapolis
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Minneapolis
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
招募中1/2 期
- M Health Fairview University of Minnesota Medical Center, Minneapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200, Minneapolis
其他城市的 头颈鳞状细胞癌试验
- Houston, TX47 项研究
- Los Angeles, CA42 项研究
- Boston, MA40 项研究
- New York City, NY39 项研究
- Nashville, TN39 项研究
- St. Louis, MO28 项研究
- Arlington, VA26 项研究
- Chicago, IL26 项研究
- Philadelphia, PA26 项研究
- Atlanta, GA24 项研究
- San Antonio, TX22 项研究
- New Haven, CT22 项研究
Minneapolis的其他研究
- 非小细胞肺癌27 项研究
- 乳腺癌27 项研究
- 卵巢癌24 项研究
- 前列腺癌23 项研究
- 癌症（所有类型）22 项研究
- 心力衰竭21 项研究
- 急性髓系白血病20 项研究
- 肺癌20 项研究
- 结直肠癌19 项研究
- 子宫内膜癌18 项研究
- 帕金森病17 项研究
- 心血管疾病15 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。